{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:49:27Z","timestamp":1768772967413,"version":"3.49.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biotechnol Lett"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10529-022-03259-6","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T15:03:31Z","timestamp":1653404611000},"page":"831-843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19"],"prefix":"10.1007","volume":"44","author":[{"given":"Prajakta","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8049-3703","authenticated-orcid":false,"given":"Sriram","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"3259_CR1","doi-asserted-by":"publisher","first-page":"103595","DOI":"10.1016\/j.ebiom.2021.103595","volume":"72","author":"R Abdelnabi","year":"2021","unstructured":"Abdelnabi R, Foo CS, Kaptein SJF et al (2021) The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of efficacy 1 in a SARS-CoV2 hamster infection model through an increased frequency of mutations in the viral 2 genome. EBioMedicine 72:103595","journal-title":"EBioMedicine"},{"key":"3259_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/pharmacy9010064","volume":"9","author":"K Abuga","year":"2021","unstructured":"Abuga K, Nyamweya N (2021) Alcohol-based hand sanitizers in COVID-19 prevention: a multidimensional perspective. Pharmacy 9:64","journal-title":"Pharmacy"},{"key":"3259_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","volume":"76","author":"U Agrawal","year":"2020","unstructured":"Agrawal U, Raju R, Udwadia ZF (2020) Favipiravir: a new and emerging antiviral option in COVID-19. Med J Armed Forces India 76:370\u2013376","journal-title":"Med J Armed Forces India"},{"key":"3259_CR4","doi-asserted-by":"publisher","first-page":"C57","DOI":"10.1152\/ajpcell.00426.2020","volume":"320","author":"S Ajaz","year":"2021","unstructured":"Ajaz S, McPhail MJ, Singh KK et al (2021) Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. Am J Physiol Cell Physiol 320:C57\u2013C65","journal-title":"Am J Physiol Cell Physiol"},{"key":"3259_CR5","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.33263\/BRIAC105.64446459","volume":"10","author":"NA Al-Masoudi","year":"2020","unstructured":"Al-Masoudi NA, Elias RS, Saeed B (2020) Molecular docking studies of some antiviral and antimalarial drugs via bindings to 3CL-protease and polymerase enzymes of the novel coronavirus (SARSCoV-2). Biointerface Res Appl Chem 10:6444\u20136459","journal-title":"Biointerface Res Appl Chem"},{"key":"3259_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12935-020-01514-2","volume":"20","author":"AG Al-Ziaydi","year":"2020","unstructured":"Al-Ziaydi AG, Al-Shammari AM, Hamzah MI et al (2020) Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells. Cancer Cell Int 20:420","journal-title":"Cancer Cell Int"},{"key":"3259_CR7","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1002\/jps.23258","volume":"101","author":"FG Bahar","year":"2012","unstructured":"Bahar FG, Ohura K, Ogihara T et al (2012) Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci 101:3979\u20133988","journal-title":"J Pharm Sci"},{"key":"3259_CR8","doi-asserted-by":"publisher","first-page":"120411","DOI":"10.1016\/j.lfs.2022.120411","volume":"295","author":"AN Bhatt","year":"2022","unstructured":"Bhatt AN, Kumar A, Rai Y et al (2022) Glycolytic inhibitor 2-Deoxy-D-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions. Life Sci 295:120411","journal-title":"Life Sci"},{"key":"3259_CR9","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","volume":"6","author":"Q Cai","year":"2020","unstructured":"Cai Q, Yang M, Liu D et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 6:1192\u20131198","journal-title":"Engineering"},{"key":"3259_CR10","doi-asserted-by":"publisher","first-page":"683296","DOI":"10.3389\/fphar.2021.683296","volume":"12","author":"C Chen","year":"2020","unstructured":"Chen C, Zhang Y, Huang J, Yin P et al (2020) Favipiravir versus arbidol for COVID-19: a randomized clinical trial. Front Pharmacol 12:683296","journal-title":"Front Pharmacol"},{"issue":"11","key":"3259_CR11","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","volume":"19","author":"M Chien","year":"2020","unstructured":"Chien M, Anderson TK, Jockusch S et al (2020) Nucleotide analogues as Inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J Proteome Res 19(11):4690\u20134697","journal-title":"J Proteome Res"},{"key":"3259_CR12","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1038\/cddis.2015.209","volume":"6","author":"L Courteau","year":"2015","unstructured":"Courteau L, Crasto J, Hassanzadeh G et al (2015) Hexokinase 2 controls cellular stress response through localization of an RNA-binding protein. Cell Death Dis 6:e1837","journal-title":"Cell Death Dis"},{"key":"3259_CR13","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1038\/s41598-021-86859-y","volume":"11","author":"IA Darazam","year":"2021","unstructured":"Darazam IA, Shokouhi S, Pourhoseingholi MA et al (2021) Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep 11:8059","journal-title":"Sci Rep"},{"issue":"1","key":"3259_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s13054-020-03078-z","volume":"24","author":"K Doi","year":"2020","unstructured":"Doi K, Ikeda M, Hayase N et al (2020) Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with COVID-19: a case series. Crit Care 24(1):392","journal-title":"Crit Care"},{"key":"3259_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2217\/fon.09.44","volume":"5","author":"BS Dwarakanath","year":"2009","unstructured":"Dwarakanath BS, Jain V (2009) Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol 5:581\u2013585","journal-title":"Future Oncol"},{"key":"3259_CR16","doi-asserted-by":"publisher","first-page":"592908","DOI":"10.3389\/fmicb.2020.592908","volume":"11","author":"AF Eweas","year":"2021","unstructured":"Eweas AF, Alhossary AA, Abdel-Moneim AS (2021) Molecular docking reveals Ivermectin and Remdesivir as potential repurposed drugs against SARS-CoV-2. Front Microbiol 11:592908","journal-title":"Front Microbiol"},{"key":"3259_CR17","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1128\/JVI.02309-14","volume":"89","author":"KA Fontaine","year":"2015","unstructured":"Fontaine KA, Sanchez EL, Camarda R et al (2015) Dengue virus induces and requires glycolysis for optimal replication. J Virol 89:2358\u20132366","journal-title":"J Virol"},{"key":"3259_CR18","doi-asserted-by":"publisher","first-page":"109348","DOI":"10.1016\/j.cbi.2020.109348","volume":"335","author":"KL Forrestall","year":"2021","unstructured":"Forrestall KL, Burley DE, Cash MK et al (2021) 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease. Chem Biol Interact 335:109348","journal-title":"Chem Biol Interact"},{"key":"3259_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K et al (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivirus Res 100:446\u2013454","journal-title":"Antivirus Res"},{"key":"3259_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B 93:449\u2013463","journal-title":"Proc Jpn Acad Ser B"},{"key":"3259_CR21","doi-asserted-by":"publisher","first-page":"109891","DOI":"10.1016\/j.biopha.2020.109891","volume":"124","author":"H Gao","year":"2020","unstructured":"Gao H, Liang D, Li C et al (2020) 2-Deoxy-Rh2: a novel ginsenoside derivative, as dual-targeting anti-cancer agent via regulating apoptosis and glycolysis. Biomed Pharmacother 124:109891","journal-title":"Biomed Pharmacother"},{"key":"3259_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s41182-020-00285-w","volume":"48","author":"T Girum","year":"2020","unstructured":"Girum T, Lentiro K, Geremew M et al (2020) Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review. Trop Med Health 48:91","journal-title":"Trop Med Health"},{"key":"3259_CR23","first-page":"4448","volume":"25","author":"S Halder","year":"2021","unstructured":"Halder S, Mehta AK (2021) 2-Deoxy-D-glucose: is this the final cure for COVID-19: or yet another mirage? Eur Rev Med Pharmacol Sci 25:4448\u20134450","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3259_CR24","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/jmv.26003","volume":"92","author":"J Huang","year":"2020","unstructured":"Huang J, Cheng A, Kumar R et al (2020) Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol 92:2152\u20132158","journal-title":"J Med Virol"},{"key":"3259_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.biochi.2020.11.010","volume":"180","author":"P Icard","year":"2021","unstructured":"Icard P, Lincet H, Wu Z et al (2021) The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. Biochimie 180:169\u2013177","journal-title":"Biochimie"},{"key":"3259_CR26","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.3390\/molecules26195795","volume":"26","author":"M Imran","year":"2021","unstructured":"Imran M, Arora MK, Asdaq SMB et al (2021) Discovery, development, and patent trends on Molnupiravir: a prospective oral treatment for COVID-19. Molecules 26:5795","journal-title":"Molecules"},{"key":"3259_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/cid\/ciaa1176","volume":"73","author":"AA Ivashchenko","year":"2020","unstructured":"Ivashchenko AA, Dmitriev KA, Vostokova NV et al (2020) AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II\/III multicenter randomized clinical trial. Clin Infect Dis 73:531\u2013534","journal-title":"Clin Infect Dis"},{"key":"3259_CR28","doi-asserted-by":"publisher","first-page":"e2024302118","DOI":"10.1073\/pnas.2024302118","volume":"118","author":"WD Jang","year":"2021","unstructured":"Jang WD, Jeon S, Kim S et al (2021) Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. PNAS 118:e2024302118","journal-title":"PNAS"},{"key":"3259_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3390\/pharmaceutics13091519","volume":"13","author":"J-H Kang","year":"2021","unstructured":"Kang J-H, Kim Y-J, Yang M-S et al (2021) Co-Spray dried Nafamostat mesylate with lecithin and mannitol as respirable microparticles for targeted pulmonary delivery: pharmacokinetics and lung distribution in rats. Pharmaceutics 13:1519","journal-title":"Pharmaceutics"},{"key":"3259_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jiph.2020.10.012","volume":"14","author":"SA Khan","year":"2021","unstructured":"Khan SA, Al-Balushi K (2021) Combating COVID-19: the role of drug repurposing and medicinal plants. J Infect Public Health 14:495\u2013503","journal-title":"J Infect Public Health"},{"key":"3259_CR31","doi-asserted-by":"publisher","first-page":"e0248358","DOI":"10.1371\/journal.pone.0248358","volume":"16","author":"M Kheir","year":"2021","unstructured":"Kheir M, Saleem F, Wang C et al (2021) Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19. PLoS ONE 16:e0248358","journal-title":"PLoS ONE"},{"key":"3259_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.micinf.2020.02.002","volume":"22","author":"J-Y Li","year":"2020","unstructured":"Li J-Y, You Z, Wang Q et al (2020) The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect 22:80\u201385","journal-title":"Microbes Infect"},{"key":"3259_CR33","first-page":"e00162","volume":"34","author":"JJ Malin","year":"2021","unstructured":"Malin JJ, Su\u00e1rez I, Priesner V et al (2021) Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev 34:e00162-e220","journal-title":"Clin Microbiol Rev"},{"key":"3259_CR34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41594-021-00657-8","volume":"28","author":"B Malone","year":"2021","unstructured":"Malone B, Campbell EA (2021) Molnupiravir: coding for catastrophe. Nat Struct Mol Biol 28:706\u2013711","journal-title":"Nat Struct Mol Biol"},{"key":"3259_CR35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/bbrj.bbrj_94_21","volume":"5","author":"MK Mantha","year":"2021","unstructured":"Mantha MK, Suvvari TK, Corriero AC (2021) 2-Deoxy-D-glucose as an armament against COVID-19: the key to return to normality? Biomed Biotechnol Res J 5:347\u2013348","journal-title":"Biomed Biotechnol Res J"},{"key":"3259_CR36","doi-asserted-by":"publisher","first-page":"622898","DOI":"10.3389\/fchem.2021.622898","volume":"9","author":"HM Mengist","year":"2021","unstructured":"Mengist HM, Dilnessa T, Jin T (2021) Structural basis of potential inhibitors targeting SARS-CoV-2 main protease. Front Chem 9:622898","journal-title":"Front Chem"},{"key":"3259_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1515\/dmdi-2014-0009","volume":"29","author":"Z Merali","year":"2014","unstructured":"Merali Z, Ross S, Par\u00e9 G (2014) The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metab Drug Interact 29:143\u2013151","journal-title":"Drug Metab Drug Interact"},{"key":"3259_CR38","doi-asserted-by":"publisher","first-page":"107930","DOI":"10.1016\/j.pharmthera.2021.107930","volume":"228","author":"YL Ng","year":"2021","unstructured":"Ng YL, Salim CK, Chu JJH (2021) Drug repurposing for COVID-19: approaches, challenges and promising candidates. Pharmacol Ther 228:107930","journal-title":"Pharmacol Ther"},{"key":"3259_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","volume":"78","author":"M Nicola","year":"2020","unstructured":"Nicola M, Alsafi Z, Sohrabi C et al (2020) The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg 78:185\u2013193","journal-title":"Int J Surg"},{"key":"3259_CR40","first-page":"1","volume":"21","author":"S Padmanabhan","year":"2021","unstructured":"Padmanabhan S (2021) Potassium levels in COVID subjects: current observations and new possibilities for its use in COVID diagnosis. Glob J Med Res 21:1\u20138","journal-title":"Glob J Med Res"},{"key":"3259_CR41","doi-asserted-by":"publisher","first-page":"104597","DOI":"10.1016\/j.antiviral.2019.104597","volume":"171","author":"GR Painter","year":"2019","unstructured":"Painter GR, Bowen RA, Bluemling GR et al (2019) The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus Infection. Antiviral Res 171:104597","journal-title":"Antiviral Res"},{"key":"3259_CR42","doi-asserted-by":"publisher","first-page":"e02428","DOI":"10.1128\/AAC.02428-20","volume":"65","author":"WP Painter","year":"2021","unstructured":"Painter WP, HolmanW BJA et al (2021) Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother 65:e02428-e2520","journal-title":"Antimicrob Agents Chemother"},{"key":"3259_CR43","first-page":"193","volume":"6","author":"SB Palghadmal","year":"2021","unstructured":"Palghadmal SB, Kulkarni PS, Makadia V et al (2021) Tackling complications of coronavirus infection with quercetin: observations and hypotheses. Explor Res Hypothesis Med 6:193\u2013204","journal-title":"Explor Res Hypothesis Med"},{"key":"3259_CR44","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3390\/molecules23081899","volume":"23","author":"T Pantsar","year":"2018","unstructured":"Pantsar T, Poso A (2018) Binding affinity via docking: fact and fiction. Molecules 23:1899","journal-title":"Molecules"},{"key":"3259_CR45","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2174\/1389557521666201222145842","volume":"21","author":"SS Paul","year":"2021","unstructured":"Paul SS, Biswas G (2021) Repurposed antiviral drugs for the treatment of COVID-19: syntheses, mechanism of infection and clinical trials. Mini Rev Med Chem 21:1123\u20131143","journal-title":"Mini Rev Med Chem"},{"key":"3259_CR46","doi-asserted-by":"publisher","first-page":"11886","DOI":"10.1021\/jp506629y","volume":"118","author":"O Phuangsawai","year":"2014","unstructured":"Phuangsawai O, Hannongbua S, Gleeson MP (2014) Elucidating the origin of the esterase activity of human serum albumin using QM\/MM calculations. J Phys Chem B 118:11886\u201311894","journal-title":"J Phys Chem B"},{"key":"3259_CR47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s42506-021-00094-x","volume":"97","author":"P Prajapati","year":"2022","unstructured":"Prajapati P, Desai H, Chandarana C (2022) Hand sanitizers as a preventive measure in COVID-19 pandemic, its characteristics, and harmful effects: a review. J Egypt Public Health Assoc 97:6","journal-title":"J Egypt Public Health Assoc"},{"key":"3259_CR48","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1124\/dmd.120.000065","volume":"48","author":"Y Qian","year":"2020","unstructured":"Qian Y, Markowitz JS (2020) Natural products as modulators of CES1 activity. Drug Metab Dispos 48:993\u20131007","journal-title":"Drug Metab Dispos"},{"key":"3259_CR49","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1007\/s11696-021-01640-9","volume":"75","author":"AM Rabie","year":"2021","unstructured":"Rabie AM (2021) Discovery of (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug. Chem Pap 75:4669\u20134685","journal-title":"Chem Pap"},{"key":"3259_CR50","first-page":"1","volume":"2020","author":"MdO Rafi","year":"2020","unstructured":"Rafi MdO, Bhattacharje G, Al-Khafaji K et al (2020) Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. J Biomol Struct Dyn 2020:1\u201320","journal-title":"J Biomol Struct Dyn"},{"key":"3259_CR51","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1128\/JVI.02862-13","volume":"88","author":"C Rami\u00e8re","year":"2014","unstructured":"Rami\u00e8re C, Rodriguez J, Enache LS et al (2014) Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. J Virol 88:3246\u20133254","journal-title":"J Virol"},{"key":"3259_CR52","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.1128\/JVI.72.8.6884-6887.1998","volume":"72","author":"PC Reading","year":"1998","unstructured":"Reading PC, Allison J, Crouch EC et al (1998) Increased susceptibility of diabetic mice to Influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose? J Virol 72:6884\u20136887","journal-title":"J Virol"},{"key":"3259_CR53","doi-asserted-by":"crossref","unstructured":"Rinkevich FD, Margotta JW, Simone-Finstrom M et al (2018) Esterase activity is affected by genetics, age, insecticide exposure, and viral infection in the honey bee, Apis mellifera. Biorxiv","DOI":"10.1101\/415356"},{"key":"3259_CR54","doi-asserted-by":"publisher","first-page":"106280","DOI":"10.1016\/j.ypmed.2020.106280","volume":"141","author":"T Sagawa","year":"2020","unstructured":"Sagawa T, Inoue KI, Takano H (2020) Use of protease inhibitors for the prevention of COVID-19. Prev Med 141:106280","journal-title":"Prev Med"},{"issue":"10","key":"3259_CR55","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.4103\/jfmpc.jfmpc_1338_21","volume":"10","author":"KK Sahu","year":"2021","unstructured":"Sahu KK, Kumar R (2021) Role of 2-Deoxy-D-Glucose (2-DG) in COVID-19 disease: a potential game-changer. J Fam Med Prim Care 10(10):3548\u20133552","journal-title":"J Fam Med Prim Care"},{"key":"3259_CR56","doi-asserted-by":"publisher","first-page":"634047","DOI":"10.3389\/fphar.2021.634047","volume":"12","author":"S Saha","year":"2021","unstructured":"Saha S, Nandi R, Vishwakarma P et al (2021) Discovering potential RNA dependent RNA polymerase inhibitors as prospective drugs against COVID-19: an in silico approach. Front Pharmacol 12:634047","journal-title":"Front Pharmacol"},{"key":"3259_CR57","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.2019.20153","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ et al (2020) Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19). A review. JAMA 323:1824\u20131836","journal-title":"JAMA"},{"key":"3259_CR58","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1128\/jvi.13.6.1186-1193.1974","volume":"13","author":"C Scholtissek","year":"1974","unstructured":"Scholtissek C, Rott R, Hau G et al (1974) Inhibition of the multiplication of vesicular stomatitis and Newcastle disease virus by 2-deoxy-D-glucose. J Virol 13:1186\u20131193","journal-title":"J Virol"},{"key":"3259_CR59","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fmolb.2020.00215","volume":"7","author":"S Seth","year":"2020","unstructured":"Seth S, Batra J, Srinivasan S (2020) COVID-19: Targeting proteases in viral invasion and host immune response. Front Mol Biosci 7:215","journal-title":"Front Mol Biosci"},{"key":"3259_CR60","doi-asserted-by":"publisher","first-page":"632043","DOI":"10.3389\/fpubh.2021.632043","volume":"9","author":"Y Shang","year":"2021","unstructured":"Shang Y, Li H, Zhang R (2021a) Effects of pandemic outbreak on economies: evidence from business history context. Front Public Health 9:632043","journal-title":"Front Public Health"},{"key":"3259_CR61","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12985-021-01515-1","volume":"18","author":"C Shang","year":"2021","unstructured":"Shang C, Zhuang X, Zhang H et al (2021b) Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology J 18:46","journal-title":"Virology J"},{"key":"3259_CR62","doi-asserted-by":"publisher","first-page":"11475","DOI":"10.3390\/ijms222111475","volume":"22","author":"T Shen","year":"2021","unstructured":"Shen T, Wang T (2021) Metabolic reprogramming in COVID-19. Int J Mol Sci 22:11475","journal-title":"Int J Mol Sci"},{"key":"3259_CR63","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/hep4.1736","volume":"5","author":"Y Shen","year":"2021","unstructured":"Shen Y, Eades W, Yan B (2021) The COVID-19 medicine Remdesivir is therapeutically activated by carboxylesterase-1, and excessive hydrolysis increases cytotoxicity. Hepatol Commun 5:1622\u20131623","journal-title":"Hepatol Commun"},{"key":"3259_CR64","doi-asserted-by":"crossref","unstructured":"Su H-X, Yao S, Zhao, W-F et al (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 1\u201311","DOI":"10.1038\/s41401-020-0483-6"},{"key":"3259_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1056\/NEJMc2119407","volume":"386","author":"E Takashita","year":"2022","unstructured":"Takashita E, Kinoshita N, Yamayoshi S et al (2022) Efficacy of antibodies and antiviral drugs against COVID-19 omicron variant. N Engl J Med 386:10","journal-title":"N Engl J Med"},{"key":"3259_CR100","doi-asserted-by":"crossref","unstructured":"Tempestilli M, Caputi P, Avataneo V et al (2020) Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75:2977\u20132980","DOI":"10.1093\/jac\/dkaa239"},{"key":"3259_CR66","doi-asserted-by":"publisher","first-page":"107697","DOI":"10.1016\/j.jmgm.2020.107697","volume":"100","author":"K Teral\u0131","year":"2020","unstructured":"Teral\u0131 K, Baddal B, G\u00fclcan HO (2020) Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. J Mol Graph Model 100:107697","journal-title":"J Mol Graph Model"},{"key":"3259_CR67","doi-asserted-by":"publisher","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","volume":"198","author":"L Vangeel","year":"2022","unstructured":"Vangeel L, Chiu W, De Jonghe S et al (2022) Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antivirus Res 198:105252","journal-title":"Antivirus Res"},{"key":"3259_CR68","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1016\/S2213-2600(21)00270-8","volume":"9","author":"P Venkatesan","year":"2021","unstructured":"Venkatesan P (2021) Repurposing drugs for treatment of COVID-19. Lancet Respir Med 9:E63","journal-title":"Lancet Respir Med"},{"key":"3259_CR69","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl A, Gralinski LE, Johnson CE et al (2021) SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591:451\u2013457","journal-title":"Nature"},{"key":"3259_CR70","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s11033-020-05361-2","volume":"47","author":"K Wanat","year":"2020","unstructured":"Wanat K (2020) Biological barriers, and the influence of protein binding on the passage of drugs across them. Mol Biol Rep 47:3221\u20133231","journal-title":"Mol Biol Rep"},{"key":"3259_CR71","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G et al (2020) Remdesivir in adults with severe COVID-19: a randomized, double blind, placebo-controlled, multicenter trial. Lancet 395:1569\u20131578","journal-title":"Lancet"},{"key":"3259_CR72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.virol.2021.09.009","volume":"564","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li P, Solanki K et al (2021) Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology 564:33\u201338","journal-title":"Virology"},{"key":"3259_CR73","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","volume":"11","author":"VC Yan","year":"2020","unstructured":"Yan VC, Muller FL (2020) Advantages of the parent nucleoside GS-441524 over Remdesivir for COVID-19 treatment. ACS Med Chem Lett 11:1361\u20131366","journal-title":"ACS Med Chem Lett"},{"key":"3259_CR74","doi-asserted-by":"publisher","first-page":"105078","DOI":"10.1016\/j.antiviral.2021.105078","volume":"190","author":"J Zhao","year":"2021","unstructured":"Zhao J, Guo SS, Yi D et al (2021) A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res 190:105078","journal-title":"Antiviral Res"},{"key":"3259_CR75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.36233\/0372-9311-114","volume":"98","author":"OP Zhirnov","year":"2021","unstructured":"Zhirnov OP, Chernyshova AI (2021) Favipiravir: the hidden threat of mutagenic action. J Microbiol Epidemiol Immunobiol 98:213\u2013220","journal-title":"J Microbiol Epidemiol Immunobiol"}],"container-title":["Biotechnology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10529-022-03259-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10529-022-03259-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10529-022-03259-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T04:23:16Z","timestamp":1700626996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10529-022-03259-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3259"],"URL":"https:\/\/doi.org\/10.1007\/s10529-022-03259-6","relation":{},"ISSN":["0141-5492","1573-6776"],"issn-type":[{"value":"0141-5492","type":"print"},{"value":"1573-6776","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"30 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by either of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving animal rights"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}